Collectively, these findings positioned sermorelin as the most promising drug candidate for recurrent glioma patients, guiding the subsequent analyses in the study [1]
Liu J, Zhang Y, Yang B, Jia Y, Liu RT, Ding L, et al
Toward understanding the origin and evolution of cellular organisms
doi: 10.3389/fcimb.2026.1752304 Received 23 November 2025 Revised 12 January 2026 Accepted 31 January 2026 Published 19 February 2026 Volume 16 - 2026 Edited by Teclegiorgis Gebremariam, Lundquist Institute for Biomedical Innovation, United States Reviewed by Fatemeh Ahangarkani, 4cyte Pathology, Australia Sanam Dolati, Lundquist Institute for Biomedical Innovation, United States Updates Copyright 2026 Wu, Jiang, Wang, Chen, Chen and Da
Przekop R, et al